Introduction
============

Bipolar disorder (BPD) is a highly heritable psychiatric illness. The genetic components were estimated to account for as high as ∼80% of phenotypic variability (McGuffin et al., [@B38]). Although many candidate and genome-wide association (GWA) studies have conducted to investigate the complex nature of pathogenetics in BPD, previously reported genetic findings only account for a small proportion of its heritability (Gershon et al., [@B16]). The missing heritability may be partially explained by the limited numbers, types, and frequency of susceptible variants that currently genotyped in high-throughput array, and other mechanisms such as gene × gene or gene × environment interactions, as well as the heterogeneity in phenotype definitions across studies (Manolio et al., [@B32]). Nevertheless, large-scale GWA studies remain to be an efficient and promising study design to uncover the underlying etiology of complex psychiatric disorders (Sullivan and Investigators, [@B54]), while new theoretical framework and statistical approaches must be taken into consideration.

Recently, pathway-based analysis, which simultaneously tests a group of functionally related genes, has been widely used as an alternative and complementary strategy to bring more insights into the biological mechanisms of disease of interest (Wang et al., [@B61]). In addition, inclusion of prior information from other aspects, such as gene expression or gene regulation in GWAS analysis offers great opportunities to identify new association findings and to generate novel hypotheses (Tintle et al., [@B57]). For instance, two prior GWA studies in type 2 diabetes and osteoporosis applied integrative approaches that used gene expression data and pathway-based analysis to identify novel associated pathways and loci (Hsu et al., [@B20]; Zhong et al., [@B64]). In addition to gene expression information, other types of data could also be incorporated into pathway-based analysis using GWA data, such as methylation (Chuang et al., [@B10]) and microRNAs (miRNAs) patterns, especially disease-associated miRNAs.

The miRNAs are one kind of functional non-coding RNAs acting as post-transcriptional regulators for translation and the stability of mRNAs, which involved in a wide range of biological processes, including regulation of brain and neuronal development (Fiore et al., [@B13]). The miRNA dysregulation has been reported to play important roles in the etiology of many diseases, including complex psychiatric traits (Xu et al., [@B63]). Previously, many psychiatric- and neurological-associated miRNAs were identified from expression studies of postmortem brain and animal models (Forero et al., [@B14]), and from genetic association studies of variants in genes encoding miRNAs and binding site of miRNAs target genes (Muinos-Gimeno et al., [@B39]; The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, [@B56]).

We have known that an individual miRNA could target hundreds of mRNA molecules (Lim et al., [@B29]), therefore the target genes of a phenotype-related miRNA may potentially associate with the trait. For example, abnormal expression level of brain-expressed miR-132 has been reported to be associated with psychiatric disorders via affecting the expression of brain-derived neurotrophic factor that is involved in dendritic plasticity (Klein et al., [@B25]; Wayman et al., [@B62]; Askland et al., [@B1]; Forero et al., [@B14]). In addition, different psychiatric disorders (e.g., schizophrenia and BPD) may share some degree of the genetic factors through the involvement of similar biological pathways. Thus, a single miRNA may play roles in the etiology of more than one psychiatric disorder. Given these features of miRNAs, it is our interest to incorporate information of phenotype-related miRNAs and their predicted targets into the GWA analysis, which provide a new avenue for researchers to investigate the underlying genetic components that are associated with BPD.

In the current study, we performed pathway-based analysis using large-scale GWA dataset of BPD in combination with the data source of miRNAs. The psychiatric- and neurological-associated miRNAs were identified from PhenomiR database and miRNA target predictions were obtained from [microRNA.org](microRNA.org) database. Our main goal is to better identify genes and important biological pathways to be associated with BPD while incorporating the regulatory information of miRNAs.

Materials and Methods
=====================

Figure [1](#F1){ref-type="fig"} shows the data integration flowchart in our study to identify the psychiatric- and neurological-associated miRNAs and their target genes, and the annotated pathways for pathway-based analysis. Details are mentioned below.

![**The flowchart of identification of psychiatric- and neurological-associated miRNAs and their target genes and information for pathway analysis**.](fgene-03-00293-g001){#F1}

Genome-wide association dataset
-------------------------------

The Genetic Association Information Network (GAIN) GWA dataset was downloaded from dbGaP[^1^](#fn1){ref-type="fn"}. We extracted BPD dataset from the GAIN: full details of subject enrollment and genotyping can be obtained in the original article (The GAIN Collaborative Research Group, [@B55]). The GWA dataset of BPD comprised 1,001 BPD cases and 1,034 controls, which used Affymetrix Genome-Wide Human SNP Array 6.0 platform for SNP (single nucleotide polymorphism) genotyping. After applying quality control filters and excluding SNPs in sexual chromosomes, there were 698,227 autosomal SNPs in the GWA dataset in our analyses.

Identification of target genes of psychiatric disease-associated miRNAs
-----------------------------------------------------------------------

Information of disease-associated miRNAs was downloaded from the PhenomiR database (Ruepp et al., [@B45]). The PhenomiR collected published miRNA-disease associations via manual curation. It annotates diseases into 22 classes according to the Online Mendelian Inheritance in Man (OMIM) Morbid Map. In our analysis, we selected all miRNAs that are associated with neurological and psychiatric classes as the candidates of disease-associated miRNAs. In total, there were 157 unique miRNAs to form 293 miRNA-disease association pairs.

The miRNA target predictions were obtained from [micorRNA.org](micorRNA.org) database[^2^](#fn2){ref-type="fn"} (Betel et al., [@B5]). The [micorRNA.org](micorRNA.org) performed miRNA target prediction using miRanda algorithm (John et al., [@B22]) and scored the likelihood of mRNA downregulation of predicted target sites by using mirSVR algorithm (Betel et al., [@B4]). The combination of miRanda-mirSVR approach has been shown to effectively identify target predictions to cover a significant number of non-canonical sites, and has competitive ability in predicting expression changes of mRNA or proteins when comparing with other target prediction methods (Betel et al., [@B4]). In total, 1,097,064 "good mirSVR score-conserved miRNA" target predictions were used in this procedure. Combining these two datasets while follows the criteria of alignment score ≥140, seed site ≥6, free energy ≤−17, and conservation score ≥0.57 (Figure [1](#F1){ref-type="fig"}), we identified 8,921 genes which were predicted to be the targets of psychiatric- and neurological-associated miRNAs.

We also used another miRNA target prediction algorithm, DIANA-microT, which considers not only strong binding (at least seven consecutive Watson-Crick base pairing nucleotides) but also weak binding ability (only six paired nucleotides or G:U wobble pairs) to predict the miRNA target genes (miTG; Maragkakis et al., [@B33],[@B34]). DIANA-microT provides scores for miTG as an indicator for the probability of being a real target site. The calculation of an overall miTG score mainly based on scoring all binding types and conservation profile of all putative miRNA recognition element (MRE) within the 3′UTR using the weighted sum method. Therefore, target genes of psychiatric- and neurological-associated miRNAs with high predictive probability in significant pathways were filtered by the DIANA-microT algorithm. We used a miTG score greater than 19 (a strict threshold) as the selection criterion, which implicates the predicted target was highly reliable being a true miRNA target.

Statistical analysis
--------------------

We used PLINK (version 1.07) to conduct single marker association analyses with additive model (Purcell et al., [@B43]). We first mapped SNPs to genes to obtain gene-level statistic for BPD using the GWA dataset in GAIN. SNPs were mapped to genes if they located within 5 kb of the 5′ upstream and 3′ downstream of a gene using NCBI human genome build 36. For each gene, the smallest *P*-value (*P*~min~) among all SNPs within the gene region was used to represent the gene-level statistic. In total, there were 304,343 SNPs assigned into 16,385 genes in the GWA dataset of BPD.

Annotated pathways were obtained from the Molecule Signature Database, MsigDB (Subramanian et al., [@B53]). MsigDB consists of several online pathway databases, including Kyoto Encyclopedia of Genes and Genomes (KEGG), BioCarta, Reactome, Gene Ontology (GO) terms, and gene sets collected from published literature. From MsigDB, we obtained 4,726 pathways that cover 22,429 genes. Pathways containing less than 10 genes or more than 380 genes were excluded to avoid bias due to extreme small or large pathway size. Thus, there were 4,051 canonical pathways in the pathway-based analyses using the GWA dataset of BPD in the present study.

Pathway-based analyses were conducted using both competitive and self-contained approaches (Wang et al., [@B61]) to capture a broader range of important pathways. The gene set enrichment analysis (GSEA), as a competitive method, first ranks *P*~min~ values of all genes from the smallest to the largest. Then, for a given pathway, an enrichment score (ES) was calculated based on gene-wise statistic values (*t*~j~), which were defined as the χ^2^ statistic of the corresponding most significant SNP to evaluate association signals (Wang et al., [@B60]). The sum-statistic (SUM) approach, as a self-contained test, sums up gene-wise statistic values (*t*~*i*~) over the set of genes $\left( {\Sigma_{i = 1}^{S}t_{i}} \right)$ in a specific pathway (Tintle et al., [@B58]). The details of calculation procedures were provided in our previous study (Kao et al., [@B23]).

Weighting procedure
-------------------

We employed a weighting scheme for genes that were predicted to be psychiatric- and neurological-associated miRNA targets in every annotated pathway. First, we calculated the overall proportion of SNPs with *P*-value \<0.05 in the whole GAIN dataset. Second, in a given gene, the proportion of significant SNPs was calculated and then compared with the proportion of significant SNPs in the whole GWA dataset to evaluate whether this gene was informative. The detail of weighting procedures was described as below. For each pathway, *n* and *m* represent the number of miTGs and non- miTGs, respectively. *K*~n~ and *K*~m~ were the number of informative genes in the n miTGs and m non-miTGs, respectively. Therefore, the proportion of informative genes in the miTGs and non-miTGs were *K*~n~/n and *K*~m~/m. The Harmonic average (H), defined as 1/\[(1/m*K*~n~) + (1/n*K*~m~)\], was used as the basis of our weighting scheme for calculating the gene-wise weights of the miRNA and non-miTGs in a pathway and to minimize the potential bias in the pathway analysis due to the variation of pathway size. If *K*~n~/n was greater than *K*~m~/m, the weights for miTGs and non-miTGs were assigned mk~n~/H and nk~m~/H, respectively. If no informative genes exist in non-miRNA genes, a weight one was assigned to non-miRNA genes; while a weight, ranging from one to six, according to the proportion of informative genes (using 0.1, 0.3, 0.5, 0.7, and 0.9 as cut-off values), was assigned to miRNA genes. Otherwise, equal weights were used for the two sets of genes.

For each pathway, weights were assigned to miTGs and non-miTGs. Then all genes were classified into S set and NS set according to their involvement in a pathway or not. When using competitive methods, genes within a pathway were compared with genes not within the pathway. Regarding to self-contained methods, only genes within the pathway were considered. A total of 5,000 permutations were performed to evaluate the empirical significance level of each pathway. To account for multiple testing issues in the analyses, algorithm proposed by Benjamini and Hochberg ([@B3]) was used to control for false discovery rate (FDR).

Results
=======

A total of 4,051 pathways were constructed and tested for associations with the risk of BPD using the GWA dataset of BPD. With the inclusion of 157 psychiatric- and neurological-associated miRNAs as the prior information into pathway-based analyses, we identified many enriched pathways for BPD. Under four testing scenarios, including weighted and non-weighted GSEA and SUM statistics, there were more than 100 significant pathways associated with BPD at the level of empirical *P*-value \< 0.01, and the number was reduced to more than 40 after FDR correction (Table [A1](#TA1){ref-type="table"} in Appendix). Comparing with non-weighting scenario, pathway analysis under the weighting scenario identified additional 20 and 223 significant pathways (FDR \< 0.01) by using GSEA and SUM methods, respectively (Table [A2](#TA2){ref-type="table"} in Appendix). Under the non-weighted scheme, the number of enriched pathways identified by both the GSEA and SUM methods with FDR \< 0.01 was 43, while the number was 38 under the weighted scheme. The union set of these enriched pathways were in total 62 pathways (Table [A3](#TA3){ref-type="table"} in Appendix), including 18 annotated GO, 7 KEGG, and 37 curated gene sets. Among these pathways, 19 significant pathways were identified by both the GSEA and SUM methods using both non-weighted and weighted scheme.

Table [1](#T1){ref-type="table"} showed 19 enriched pathways with stringent criterion of FDR \< 0.01, including four GO gene sets and 15 curated gene sets, which exhibited strong associations with BPD under all four statistical scenarios. The three significant GO gene sets, cation transmembrane transporter activity, gated channel activity, and ion transmembrane transporter activity, were ion channel/transporter related. The fourth GO gene set was nervous system development, which was reported to be associated with BPD previously. After performing our weighting scheme, 19 additional pathways were identified at the significance level of FDR \< 0.01 (Table [2](#T2){ref-type="table"}), including six annotated GO, 3 KEGG, and 10 curated gene sets. Many of them are novel findings for BPD, such as cytoskeleton, retinol metabolism, drug metabolism other enzymes, etc. In total, we found 38 significant enriched pathways for BPD.

###### 

**Enriched pathways with FDR~BH~ \< 0.01 under weighted and non-weighted scenarios using GSEA and SUM methods**.

  Pathway                                          Type      No. of genes in pathway   No. of miRNA target genes   No. of non-miRNA target genes   \% of miRNA target genes[\*](#tfn1){ref-type="table-fn"}   GSEA     SUM                                                   
  ------------------------------------------------ --------- ------------------------- --------------------------- ------------------------------- ---------------------------------------------------------- -------- -------- -------- -------- -------- -------- -------- --------
  Cation transmembrane transporter activity        GO        211                       109                         85                              56.2                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  Gated channel activity                           GO        121                       55                          59                              48.2                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  Ion transmembrane transporter activity           GO        275                       128                         123                             51.0                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  Nervous system development                       GO        382                       191                         135                             58.6                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  Acevedo liver cancer with H3K27ME3 up            Curated   295                       109                         105                             50.9                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  Acevedo liver cancer with H3K9ME3 up             Curated   141                       50                          55                              47.6                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  Bertucci medullary Vs. ductal breast cancer dn   Curated   177                       88                          54                              62.0                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  Dacosta UV response Via. ERCC3 TTD DN            Curated   76                        50                          19                              72.5                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  HAMAI apoptosis VIA trail UP                     Curated   334                       176                         134                             56.8                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  Lindgren bladder cancer cluster 3 DN             Curated   223                       98                          86                              53.3                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  Manalo hypoxia UP                                Curated   211                       123                         58                              68.0                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  Martinez response to trabectedin                 Curated   42                        26                          13                              66.7                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  RIGGI ewing sarcoma progenitor UP                Curated   429                       222                         133                             62.5                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  Siligan bound by EWS FLT fusion                  Curated   36                        18                          16                              52.9                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  Vecchi gastric cancer early DN                   Curated   394                       161                         125                             56.3                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  Verhaak AML with NPM1 mutated DN                 Curated   266                       130                         93                              58.3                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  Wang SMARCE1 targets UP                          Curated   170                       92                          52                              63.9                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4
  Onder CDH1 signaling via CTNNB1                  Curated   85                        45                          31                              59.2                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   0.003
  Sabates colorectal adenoma DN                    Curated   292                       118                         112                             51.3                                                       \<2e−4   \<2e−4   \<2e−4   \<2e−4   \<2e−4   0.006    \<2e−4   \<2e−4

*\*Proportion of miRNA target genes was obtained by calculating the number of miRNA target genes divided by the total number of miRNA target genes plus non-miRNA target genes*.

*GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; GSEA, gene set enrichment analysis; SUM, sum-statistic approach; FDR~BH~, correct for false discovery rates using Benjamini & Hochberg's method*.

*Empirical *P*-value and FDR~BH~ "\<2e−4" meant that no one had greater score than the actual score among the 5,000 permutations for the analysis of each pathway*.

###### 

**Enriched pathways with FDR~BH~\<0.01 level under weighting scheme using both GSEA and SUM methods**.

  Pathway                                   Type      No. of genes in pathway   No. of miRNA target genes   No. of non-miRNA target genes   \% of miRNA target genes[\*](#tfn2){ref-type="table-fn"}   GSEA         SUM                                                                           
  ----------------------------------------- --------- ------------------------- --------------------------- ------------------------------- ---------------------------------------------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------
  Synaptic transmission                     GO        172                       77                          81                              48.7                                                       **\<2e-4**   0.021        **\<2e-4**   **\<2e-4**   **\<2e-4**   **0.006**    **\<2e-4**   **\<2e-4**
  Neurological system process               GO        377                       139                         202                             40.8                                                       **\<2e-4**   0.021        **\<2e-4**   **\<2e-4**   **\<2e-4**   0.021        **0.001**    **\<2e-4**
  Ion channel activity                      GO        147                       70                          69                              50.4                                                       **0.001**    0.036        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  Substrate specific channel activity       GO        154                       74                          72                              50.7                                                       **0.001**    0.041        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  Transmission of nerve impulse             GO        187                       83                          90                              48.0                                                       **0.001**    0.041        **\<2e-4**   **\<2e-4**   **\<2e-4**   0.018        **0.001**    **\<2e-4**
  Cytoskeleton                              GO        361                       173                         150                             53.6                                                       0.030        0.285        **\<2e-4**   **\<2e-4**   **\<2e-4**   0.252        0.042        **\<2e-4**
  Neuroactive ligand receptor interaction   KEGG      272                       94                          144                             39.5                                                       **\<2e-4**   0.021        **\<2e-4**   **\<2e-4**   **\<2e-4**   0.123        0.012        **\<2e-4**
  Retinol metabolism                        KEGG      64                        19                          38                              33.3                                                       **0.001**    0.029        **\<2e-4**   **\<2e-4**   **\<2e-4**   0.215        0.032        **\<2e-4**
  Drug metabolism other enzymes             KEGG      51                        20                          24                              45.5                                                       **0.002**    0.057        **\<2e-4**   **\<2e-4**   **\<2e-4**   0.425        0.105        **\<2e-4**
  Hatada methylated in lung cancer up       Curated   367                       161                         144                             52.8                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **0.001**    0.014        **\<2e-4**   **\<2e-4**
  Delys thyroid cancer DN                   Curated   214                       109                         86                              55.9                                                       **\<2e-4**   0.013        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  Horiuchi WTAP targets up                  Curated   323                       147                         119                             55.3                                                       **\<2e-4**   0.013        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  Thum systolic heart failure DN            Curated   248                       136                         61                              69.0                                                       **0.001**    0.029        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  Iwanaga carcinogenesis by KRAS Pten DN    Curated   445                       161                         119                             57.5                                                       **0.001**    0.036        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  Doane response to androgen DN             Curated   248                       119                         94                              55.9                                                       **0.006**    0.116        **\<2e-4**   **\<2e-4**   **0.001**    0.021        **\<2e-4**   **\<2e-4**
  Foster inflammatory response LPS DN       Curated   486                       219                         122                             64.2                                                       0.017        0.205        **\<2e-4**   **\<2e-4**   **\<2e-4**   **0.006**    **\<2e-4**   **\<2e-4**
  Acevedo liver cancer with H3K27ME3 DN     Curated   226                       73                          87                              45.6                                                       0.019        0.216        **\<2e-4**   **\<2e-4**   0.210        0.615        **\<2e-4**   **\<2e-4**
  Boylan multiple myeloma C D DN            Curated   328                       100                         113                             46.9                                                       0.020        0.224        **\<2e-4**   **\<2e-4**   0.027        0.196        **0.001**    **0.009**
  Yauch hedgehog signaling paracrine DN     Curated   385                       104                         108                             49.1                                                       0.058        0.396        **\<2e-4**   **\<2e-4**   **\<2e-4**   **0.006**    **\<2e-4**   **\<2e-4**

*\*Proportion of miRNA target genes was obtained by calculating the number of miRNA target genes divided by the total number of miRNA target genes plus non-miRNA target genes*.

*Empirical *P*-value or FDR~BH~ with values less than 0.01 were shown in bold*.

*GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; GSEA, gene set enrichment analysis; SUM, sum-statistic approach; FDR~BH~, correct for false discovery rates using Benjamini & Hochberg's method*.

*Empirical *P*-value and FDR~BH~ "\<2e−4" meant that no one had greater score than the actual score among the 5,000 permutations for the analysis of each pathway*.

miRNA target prediction
-----------------------

The results of miRNA target predictions in 38 enriched pathways were further examined. Initially, miRNA target prediction was performed by using miRanda-mirSVR approach with previously described filtering criteria (Figure [1](#F1){ref-type="fig"}). There were 2,438 unique genes in 38 significantly enriched pathways. Among them, 546 had *P*~min~-value less than 0.01. Table [3](#T3){ref-type="table"} summarized the results of miRNA target predictions for these 546 genes. On average, 34.4% of the predicted miTGs had *P*~min~-value less than 0.01 in enriched pathways, indicating a higher probability of showing associations with BPD. As expected, the larger the numbers of genes or the numbers of miTGs in a pathway, the higher number of miRanda-mirSVR prediction was observed (correlation coefficient = 0.74 and 0.82, respectively) in the 38 enriched pathways. We then applied the second prediction algorithm, DIANA-microT, to increase the stringency of target genes prediction. These results were also shown in Table [3](#T3){ref-type="table"}. By using the strict threshold at miTG score 19, we filtered out the predictions with less probability of correct prediction. Among the 38 pathways, as high as 88.9% of the miRanda-mirSVR predictions could be also predicted by DIANA-microT (ranged from 36.8 to 88.9%). The numbers of miRNA target predictions were also reduced (from 0 to 28). In total, there were 469 miRNA target predictions with miTG score \>19 for genes with *P*~min~-value of target gene \<0.01, which consisted of 113 unique genes and 45 miRNAs. Among these predictions, 22 miTGs were involved in more than three enriched pathways. The 22 miTGs and their corresponding associated miRNAs are displayed in Table [4](#T4){ref-type="table"}. The functions of these genes are mainly related to potassium and calcium ion channels (e.g., *KCNMA1*, *KCNQ5*, *KCNK2*, *PKD2*, and *RYR3*), collagen (e.g., *COL1A2*, *COL27A1*, and *COL5A1*), and axon guidance (e.g., *NF1B*, *NAV3*, and *PTPRD*).

###### 

**Predictions of psychiatric- and neurological-associated miRNA target genes with *P*~min~ \< 0.01 in 38 significantly enriched pathways**.

  Pathway                                                              No. of genes in pathway   No. of miRNA target genes   Genes with *P*~min~ \< 0.01              
  -------------------------------------------------------------------- ------------------------- --------------------------- ----------------------------- ---- ----- ----
  **ALL PATHWAY FDR~BH~ \< 0.01**                                                                                                                                     
  Cation transmembrane transporter activity                            211                       109                         32                            49   87    5
  Gated channel activity                                               121                       55                          20                            41   56    5
  Ion transmembrane transporter activity                               275                       128                         36                            49   100   6
  Nervous system development                                           382                       191                         63                            70   278   28
  Acevedo liver cancer with H3K27ME3 up                                295                       109                         42                            76   173   26
  Acevedo liver cancer with H3K9ME3 up                                 141                       50                          19                            49   72    7
  Bertucci medullary vs. ductal breast cancer DN                       177                       88                          33                            64   111   15
  Dacosta UV response via ERCC3 TTD DN                                 76                        50                          24                            56   105   26
  Hamai apoptosis via trail up                                         334                       176                         41                            68   159   9
  Lindgren bladder cancer cluster 3 DN                                 223                       98                          32                            57   117   17
  Manalo hypoxia up                                                    211                       123                         37                            65   123   10
  Martinez response to trabectedin                                     42                        26                          15                            38   52    8
  Riggi ewing sarcoma progenitor up                                    429                       222                         69                            83   290   21
  Siligan bound by ews FLT1 fusion                                     36                        18                          14                            47   68    16
  Vecchi gastric cancer early DN                                       394                       161                         47                            69   169   10
  Verhaak AML with NPM1 mutated DN                                     266                       130                         35                            62   119   2
  Wang SMARCE1 targets up                                              170                       92                          29                            54   99    17
  Onder CDH1 signaling via CTNNB1                                      85                        45                          13                            37   47    11
  Sabates colorectal adenoma DN                                        292                       118                         38                            62   130   12
  **GSEA-WEIGHTED FDR~BH~ \< 0.01 AND SUM-WEIGHTED FDR~BH~ \< 0.01**                                                                                                  
  Synaptic transmission                                                172                       77                          26                            61   126   8
  Neurological system process                                          377                       139                         49                            69   225   12
  Ion channel activity                                                 147                       70                          22                            42   65    5
  Substrate specific channel activity                                  154                       74                          22                            42   65    5
  Transmission of nerve impulse                                        187                       83                          28                            61   128   8
  Cytoskeleton                                                         361                       173                         36                            68   160   7
  Neuroactive ligand receptor interaction                              272                       94                          28                            58   112   2
  Retinol metabolism                                                   64                        19                          12                            11   19    3
  Drug metabolism other enzymes                                        51                        20                          13                            11   20    0
  Hatada methylated in lung cancer up                                  367                       161                         41                            67   120   22
  Delys thyroid cancer dn                                              214                       109                         42                            67   168   20
  Horiuchi wtap targets up                                             323                       147                         48                            73   213   23
  Thum systolic heart failure dn                                       248                       136                         41                            77   192   12
  Iwanaga carcinogenesis by kras pten DN                               445                       161                         39                            65   133   28
  Doane response to androgen dn                                        248                       119                         29                            53   101   7
  Foster inflammatory response LPS DN                                  486                       219                         43                            73   169   22
  Acevedo liver cancer with H3K27ME3 DN                                226                       73                          20                            51   102   18
  Boylan multiple myeloma C D DN                                       328                       100                         23                            54   83    8
  Yauch hedgehog signaling Paracrine DN                                385                       104                         30                            60   123   8

*\*DIANA-microT algorithm was applied to the predictions obtained by using miRanda-mirSVR approach with miTG score \> 19 (the prediction score of a miRNA and its trarget gene calculated by DIANA-microT algorithm)*.

###### 

**List of miRNA target genes and associated miRNAs in 38 significantly enriched pathways**.

  Gene symbol   Gene description                                                                     Pathway count   *P*~min~   miRNA                                                                     
  ------------- ------------------------------------------------------------------------------------ --------------- ---------- -------------- -------------- ------------- -------------- -------------- -------------
  KCNQ5         Potassium voltage-gated channel, KQT-like subfamily, member 5                        8               0.00212    hsa-miR-181c   hsa-miR-181d                                               
  PKD2          Polycystic kidney disease 2                                                          7               0.00765    hsa-miR-106b   hsa-miR-20b                                                
  RYR3          Ryanodine receptor 3                                                                 6               0.00038    hsa-miR-124                                                               
  CNTN4         Contactin 4                                                                          5               0.00065    hsa-miR-148b                                                              
  JAG1          Jagged 1                                                                             5               0.00020    hsa-miR-26b                                                               
  KCNMA1        Potassium large conductance calcium-activated channel, subfamily M, alpha member 1   5               0.00112    hsa-miR-106a   hsa-miR-17     hsa-miR-93                                  
  COL1A2        Collagen, type I, alpha 2                                                            5               0.00316    hsa-let-7b     hsa-miR-29a    hsa-miR-29b   hsa-miR-29c                   
  COL27A1       Collagen, type XXVII, alpha 1                                                        4               0.00022    hsa-let-7b     hsa-let-7i                                                 
  COL5A1        Collagen, type V, alpha 1                                                            4               0.00141    hsa-miR-29a    hsa-miR-29b    hsa-miR-29c                                 
  DLC1          Deleted in liver cancer 1                                                            4               0.00271    hsa-miR-429                                                               
  KIF1B         Kinesin family member 1B                                                             4               0.00558    hsa-miR-15a    hsa-miR-497                                                
  ABCA1         ATP-binding cassette, subfamily A (ABC1), member 1                                   3               0.00908    hsa-miR-17                                                                
  ANK2          Ankyrin 2, neuronal                                                                  3               0.00029    hsa-miR-106a   hsa-miR-9      hsa-miR-93                                  
  FLRT2         Fibronectin leucine rich transmembrane protein 2                                     3               0.00395    hsa-miR-101                                                               
  JARID2        Jumonji, AT rich interactive domain 2                                                3               0.00638    hsa-miR-130a                                                              
  KCNK2         Potassium channel, subfamily K, member 2                                             3               0.00773    hsa-miR-27a    hsa-miR-27b                                                
  MYO10         Myosin X                                                                             3               0.00697    hsa-miR-124                                                               
  NAV3          Neuron navigator 3                                                                   3               0.00691    hsa-miR-29a    hsa-miR-29b    hsa-miR-29c                                 
  NFIB          Nuclear factor I/B                                                                   3               0.00306    hsa-miR-25     hsa-miR-29b    hsa-miR-363                                 
  PAPPA         Pregnancy-associated plasma protein A, pappalysin 1                                  3               0.00112    hsa-miR-15a    hsa-miR-15b                                                
  PTPRD         Protein tyrosine phosphatase, receptor type, D                                       3               0.00148    hsa-let-7b     hsa-let-7g     hsa-let-7i    hsa-miR-106a   hsa-miR-106b   hsa-miR-124
                                                                                                                                hsa-miR-133b   hsa-miR-17     hsa-miR-20b   hsa-miR-26b    hsa-miR-93     
  ZFHX3         Zinc finger homeobox 3                                                               3               0.00175    hsa-miR-15a    hsa-miR-15b    hsa-miR-195   hsa-miR-27a    hsa-miR-27b    hsa-miR-381

*Only miRNA target genes with *P*~min~ \< 0.01 and involved in at least three pathways were listed*.

Discussion
==========

Analyzing GWA dataset with pathway-based approach utilizes information of multiple loci with similar physiological functions to bring biological insights into the mechanisms of BPD (Torkamani et al., [@B59]; Askland et al., [@B1]; Holmans et al., [@B19]; Peng et al., [@B42]). Integrating other data sources into the analysis framework further offers more opportunities in identifying disease-associated loci (Wang et al., [@B61]). The current study especially focuses on information obtained from miRNAs, which are essential in the regulation processes of brain and neuronal development. We performed pathway-based analyses using a GWA dataset of BPD while incorporating the disease-associated miRNA information into analysis. Many important pathways were identified through our analysis framework.

First, four enriched GO terms were identified for BPD, including cation transmembrane transporter activity, gated channel activity, ion transmembrane transporter activity, and nervous system development. Three of them are ion channel/transporter related. Adding the weighting scheme by miRNA information, we further identified two channel-related pathways (Table [2](#T2){ref-type="table"}), ion channel activity and substrate specific channel activity. The involvement of ion channels in the etiology of BPD was also implicated in other studies for BPD (Askland et al., [@B1]). We have known that ion channels and transporters are essential components in regulating neuronal excitability. Abnormality of ion channels has been suggested to be a plausible mechanism underlying BPD. To explain the recurrence and cycling nature of mood episodes in BPD, a kindling model was proposed as these clinical conditions are the consequences of neuronal hyperexcitability, which is linked to abnormal functions of ion channels (Mazza et al., [@B37]; Blumenfeld et al., [@B7]). Similarly, results in recent GWA and gene expression studies also support the involvement of ion channel genes in the etiology of BPD (Sklar et al., [@B51], [@B50]; Smolin et al., [@B52]). Thus, genes in the ion channels or their regulatory loci have been attractive candidates in studying the underlying mechanism for BPD. Our miTGs prediction grants further support for this line of evidence.

In our identified 38 significantly enriched pathways, many miTGs were functionally related to ion channels, especially for potassium (e.g., *KCNMA1*, *KCNQ5*, and *KCNK2*) and calcium (e.g., *RYR3* and *PKD2*) channels. All these genes involved in multiple significant pathways. For instance, *KCNMA1* is a calcium-activated potassium channel and *KCNQ5* belongs to the voltage-gated delayed rectifier potassium channel gene family. Both of them play important roles in the regulation of neuronal excitability (Laumonnier et al., [@B26]; Brown and Passmore, [@B9]). Molecular and functional studies found that defects of *KCNMA1* contribute to autism and mental retardation (Laumonnier et al., [@B26]). For *KCNK2* gene that encodes for a two-pore-domain background potassium channel, a recent genetic study revealed its association with susceptibility of major depressive disorder and response to antidepressant treatment (Liou et al., [@B30]). Additionally, several susceptible genes that cause abnormality in calcium signaling, such as *CACNA1C* and *Bcl-2*, were reported to be associated with BPD (Sklar et al., [@B51], [@B50]; Distelhorst and Bootman, [@B11]). *RYR3*, a brain-specific ryanodine receptor for controlling intracellular calcium concentration, was found to be a susceptible gene for schizophrenia (Leonard and Freedman, [@B27]). In addition, the RYR3 knockout mice exhibited some abnormal behaviors, including hyperlocomoter activity and decreased social interaction (Matsuo et al., [@B36]). Although how these behaviors defects and functional defects of ion channels link with the pathology of BPD are still unclear, it warrants to conduct further basic and functional research to investigate the roles of ion channels in BPD.

Second, applying the weighting scheme for psychiatric- and neurological-associated miRNAs in the analysis, we identified several significant pathways for BPD that were involved many nervous related biological processes in Table [2](#T2){ref-type="table"} (Li et al., [@B28]; Nakatani et al., [@B40]; Ryan et al., [@B46]; Bremner and McCaffery, [@B8]; Ramocki and Zoghbi, [@B44]; Torkamani et al., [@B59]; Askland et al., [@B1]). Some pathways are novel findings for BPD but show their biological plausibility to neurological disorders in general, such as retinol metabolism (Maden, [@B31]), while other pathways are novel findings specific to BPD (not reported in other neurological disorders, such as drug metabolism other enzymes). Of note, it is known that necessity of cytoskeletal modulation play a role in the processes of nervous system development (Ramocki and Zoghbi, [@B44]). Additionally, neuroactive ligand receptor interaction pathway was reported to be associated with substance addiction, which is commonly observed comorbid condition in BPD patients (Li et al., [@B28]).

The miRNA regulation potentially contributes to the functions of these associated pathways in BPD. Recent findings exhibited the essential roles of miRNA machinery in many aspects of nervous system, including Dicer and miR-124 in neuronal development and miR-134 in synaptic development (Gao, [@B15]; Saba and Schratt, [@B47]). Regulation of calcium channel gene expression by miR-103 was also reported (Favereaux et al., [@B12]). In addition to enriched GO and KEGG pathways, we also identified many significant pathways that were obtained from curated data in the literature in MsigDB, which was mainly based on gene expression studies related with multiple cancers. Examining the functions of miRNA-associated genes in these enriched pathways suggested the involvement of different miRNA regulation in the etiology of BPD, including Notch signaling (e.g., *JAG1*), axonal growth, and guidance (e.g., *CNTN4*, *NFIB*, *NAV3*, and *PTPRD*), and cholesterol homeostasis (e.g., *ABCA1*) (Hekimi and Kershaw, [@B18]; Bixby, [@B6]; Karasinska et al., [@B24]; Mason et al., [@B35]; Shimoda and Watanbbe, [@B48]; Pedroso et al., [@B41]). In addition, our identified BPD-associated pathways consisted of many collagen related genes, such as *COL1A2*, *COL27A1*, and *COL5A1*, implicating that these genes may augment their impacts on BPD through miRNA regulation. Although the connection of collagen and BPD was rarely reported in the literature, the emerging data and evidence, came from *in vivo* studies suggested that collagen joined the processes of axonal growth and guidance, synaptogenesis, and Schwann cell myelination during the development of nervous system (Hubert et al., [@B21]).

Among these identified miTGs (in Table [4](#T4){ref-type="table"}), some of them have been previously linked to the regulation of miRNA machinery. A recent study showed the mediation of miR-34a and miR-21 on expression of *JAG1*, to regulate the differentiation of human monocyte-derived dendritic cell, which is involved in five of our identified curated gene sets (Hashimi et al., [@B17]). In addition, increased expression of *NAV3* mRNA was observed in brain tissue of Alzheimer's disease and was suggested to be regulated by miR-29a (Shioya et al., [@B49]). On the contrary, the links between miRNAs and BPD were rarely constructed. Most of psychiatric- and neurological-associated miRNAs used in this study were reported to be related to schizophrenia, Alzheimer disease, autism, and Parkinson disease (according to PhenomiR database). Future studies are also needed to uncover the impacts of these miRNAs on the etiology of BPD.

There are some limitations in the present study. First, *P*~min~-value was used to represent the significance level of a gene. The information of other SNPs in a gene region may be missed. Nevertheless, previous studies showed that using *P*~min~-value in pathway analysis provides consistent results with other measures of gene-level statistic (Torkamani et al., [@B59]; Baranzini et al., [@B2]). Second, despite using more comprehensive pathway (e.g., MsigDB) and miRNA-disease/phenotype (e.g., PhenomiR) databases, the incompleteness of annotated pathways and miRNA-disease/phenotype information could have impacts on the correctness of the identified BPD-associated pathways. Third, the target genes of psychiatric- and neurological-associated miRNAs were predicted by computational methods. Although we used two miRNA target prediction algorithms to increase the correctness of prediction, further experimental validation by using functional studies are still needed in the future.

In conclusion, with integrating currently known psychiatric- and neurological-associated miRNAs as prior information, our pathway-based analyses using the GWA dataset of BPD identified not only previously reported pathways, but also new pathways that showed intriguing biological plausibility for BPD. So far, miRNAs studies in BPD are still in the infant stage. Our findings provided further evidence and support for exploring the roles of miRNA regulation in relation to nervous system for the risk of developing bipolar illness, especially ion channel regulation and axonal development. More, investigations remain to be done to elucidate the functions of these candidate pathways and genes, and the potential mechanisms involved with miRNA-mediated regulation.
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###### 

**Number of pathways at different cut-off in four statistical scenarios (total number of pathways = 4051)**.

  Significance criterion        GSEA   SUM         
  ----------------------------- ------ ----- ----- -----
  Empirical *P*-value \< 0.01   267    269   353   675
  FDR~BH~ \< 0.01               48     40    140   363

*GSEA, gene set enrichment analysis; SUM, sum-statistic approach; FDR~BH~, false discovery rate with control of multiple testing by using Benjamini & Hochberg's method*.

###### 

**Number of pathways identified by GSEA or SUM methods at significant level of 0.01 under weighted and non-weighted schemes (total number of pathways = 4051)**.

  Non-weighted          Weighted                       
  --------------------- ---------- ------ ----- ------ -----
  Empirical *P*-value   ≥0.01      3685   99    3374   324
                        \<0.01     97     170   2      351
  FDR~BH~               ≥0.01      3983   20    3688   223
                        \<0.01     28     20    0      140

*FDR~BH~, false discovery rate with control of multiple testing by using Benjamini & Hochberg's method*.

###### 

**Sixty-two enriched pathways at a FDR~BH~ \< 0.01 level under weighted and non-weighted scenarios using GSEA and SUM methods**.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pathway                               Type      No. of genes in pathway   No. of miRNA target genes   No. of non-miRNA target genes   \% of miRNA target genes[\*](#tfn4){ref-type="table-fn"}   GSEA         SUM                                                                           
  ------------------------------------- --------- ------------------------- --------------------------- ------------------------------- ---------------------------------------------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------
  GO_CATION_TRANSMEMBRANE\_\            GO        211                       109                         85                              56.2                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  TRANSPORTER_ACTIVITY                                                                                                                                                                                                                                                                        

  GO_GATED_CHANNEL_ACTIVITY             GO        121                       55                          59                              48.2                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  GO_ION_TRANSMEMBRANE\_\               GO        275                       128                         123                             51.0                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  TRANSPORTER_ACTIVITY                                                                                                                                                                                                                                                                        

  GO_NERVOUS_SYSTEM_DEVELOPMENT         GO        382                       191                         135                             58.6                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  GO_SUBSTRATE_SPECIFIC\_\              GO        341                       151                         157                             49.0                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   0.014        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  TRANSMEMBRANE_TRANSPORTER_ACTIVITY                                                                                                                                                                                                                                                          

  GO_GTPASE_REGULATOR_ACTIVITY          GO        117                       65                          41                              61.3                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   0.023        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  GO_POTASSIUM_CHANNEL_ACTIVITY         GO        50                        30                          19                              61.2                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   0.023        **\<2e-4**   **0.006**    **\<2e-4**   **0.005**

  GO_SUBSTRATE_SPECIFIC\_\              GO        388                       166                         184                             47.4                                                       **\<2e-4**   **\<2e-4**   **0.001**    0.030        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  TRANSPORTER_ACTIVITY                                                                                                                                                                                                                                                                        

  GO_VOLTAGE_GATED_POTASSIUM\_\         GO        40                        21                          17                              55.3                                                       **\<2e-4**   0.013        **\<2e-4**   0.014        **\<2e-4**   **\<2e-4**   **\<2e-4**   **0.003**
  CHANNEL_COMPLEX                                                                                                                                                                                                                                                                             

  GO_SYNAPTIC_TRANSMISSION              GO        172                       77                          81                              48.7                                                       **\<2e-4**   0.021        **\<2e-4**   **\<2e-4**   **\<2e-4**   **0.006**    **\<2e-4**   **\<2e-4**

  GO_NEUROLOGICAL_SYSTEM_PROCESS        GO        377                       139                         202                             40.8                                                       **\<2e-4**   0.021        **\<2e-4**   **\<2e-4**   **0.001**    0.021        **\<2e-4**   **\<2e-4**

  GO_ION_CHANNEL_ACTIVITY               GO        147                       70                          69                              50.4                                                       **0.001**    0.036        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  GO_SUBSTRATE_SPECIFIC_CHANNEL\_\      GO        154                       74                          72                              50.7                                                       **0.001**    0.041        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  ACTIVITY                                                                                                                                                                                                                                                                                    

  GO_TRANSMISSION_OF_NERVE_IMPULSE      GO        187                       83                          90                              48.0                                                       **0.001**    0.041        **\<2e-4**   **\<2e-4**   **0.001**    0.018        **\<2e-4**   **\<2e-4**

  GO_NEUROGENESIS                       GO        93                        46                          40                              53.5                                                       **\<2e-4**   **\<2e-4**   **0.003**    0.084        **\<2e-4**   **0.006**    **\<2e-4**   **\<2e-4**

  GO_GENERATION_OF_NEURONS              GO        83                        42                          34                              55.3                                                       **\<2e-4**   **\<2e-4**   **0.005**    0.109        **\<2e-4**   **0.006**    **\<2e-4**   **\<2e-4**

  GO_NEURON_DIFFERENTIATION             GO        76                        38                          31                              55.1                                                       **\<2e-4**   **\<2e-4**   0.011        0.153        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  GO_CYTOSKELETON                       GO        361                       173                         150                             53.6                                                       0.030        0.285        **\<2e-4**   **\<2e-4**   0.042        0.252        **\<2e-4**   **\<2e-4**

  KEGG_CALCIUM_SIGNALING_PATHWAY        KEGG      178                       80                          73                              52.3                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   0.014        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  KEGG_ECM_RECEPTOR_INTERACTION         KEGG      84                        48                          32                              60.0                                                       **\<2e-4**   **\<2e-4**   0.011        0.153        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  KEGG_ARRHYTHMOGENIC_RIGHT\_\          KEGG      76                        42                          28                              60.0                                                       **\<2e-4**   **\<2e-4**   0.044        0.287        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  VENTRICULAR_CARDIOMYOPAT_ARVC                                                                                                                                                                                                                                                               

  KEGG_FOCAL_ADHESION                   KEGG      201                       114                         66                              63.3                                                       **\<2e-4**   **\<2e-4**   0.065        0.330        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  KEGG_NEUROACTIVE_LIGAND_RECEPTOR\_\   KEGG      272                       94                          144                             39.5                                                       **\<2e-4**   0.021        **\<2e-4**   **\<2e-4**   0.012        0.123        **\<2e-4**   **\<2e-4**
  INTERACTION                                                                                                                                                                                                                                                                                 

  KEGG_RETINOL_METABOLISM               KEGG      64                        19                          38                              33.3                                                       **0.001**    0.029        **\<2e-4**   **\<2e-4**   0.032        0.215        **\<2e-4**   **\<2e-4**

  KEGG_DRUG_METABOLISM_OTHER\_\         KEGG      51                        20                          24                              45.5                                                       **0.002**    0.057        **\<2e-4**   **\<2e-4**   0.105        0.425        **\<2e-4**   **\<2e-4**
  ENZYMES                                                                                                                                                                                                                                                                                     

  ACEVEDO_LIVER_CANCER_WITH\_\          Curated   295                       109                         105                             50.9                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  H3K27ME3_UP                                                                                                                                                                                                                                                                                 

  ACEVEDO_LIVER_CANCER_WITH\_\          Curated   141                       50                          55                              47.6                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  H3K9ME3_UP                                                                                                                                                                                                                                                                                  

  BERTUCCI_MEDULLARY_VS_DUCTAL\_\       Curated   177                       88                          54                              62.0                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  BREAST_CANCER_DN                                                                                                                                                                                                                                                                            

  DACOSTA_UV_RESPONSE_VIA_ERCC3\_\      Curated   76                        50                          19                              72.5                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  TTD_DN                                                                                                                                                                                                                                                                                      

  HAMAI_APOPTOSIS_VIA_TRAIL_UP          Curated   334                       176                         134                             56.8                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  LINDGREN_BLADDER_CANCER_CLUSTER\_\    Curated   223                       98                          86                              53.3                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e−4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  3_DN                                                                                                                                                                                                                                                                                        

  MANALO_HYPOXIA_UP                     Curated   211                       123                         58                              68.0                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  MARTINEZ_RESPONSE_TO_TRABECTEDIN      Curated   42                        26                          13                              66.7                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  RIGGI_EWING_SARCOMA_PROGENITOR_UP     Curated   429                       222                         133                             62.5                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  SILIGAN_BOUND_BY_EWS_FLT1_FUSION      Curated   36                        18                          16                              52.9                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  VECCHI_GASTRIC_CANCER_EARLY_DN        Curated   394                       161                         125                             56.3                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  VERHAAK_AML_WITH_NPM1_MUTATED_DN      Curated   266                       130                         93                              58.3                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  WANG_SMARCE1_TARGETS_UP               Curated   170                       92                          52                              63.9                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  ONDER_CDH1_SIGNALING_VIA_CTNNB1       Curated   85                        45                          31                              59.2                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **0.003**

  SABATES_COLORECTAL_ADENOMA_DN         Curated   292                       118                         112                             51.3                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **0.006**    **\<2e-4**   **\<2e-4**

  HATADA_METHYLATED_IN_LUNG_CANCER_UP   Curated   367                       161                         144                             52.8                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **0.001**    0.014        **\<2e-4**   **\<2e-4**

  ONDER_CDH1_TARGETS_2\_UP              Curated   259                       140                         79                              63.9                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   0.014        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  STARK_PREFRONTAL_CORTEX_22Q11\_\      Curated   212                       122                         40                              75.3                                                       **\<2e-4**   **\<2e-4**   **\<2e-4**   0.014        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  DELETION_UP                                                                                                                                                                                                                                                                                 

  JAATINEN_HEMATOPOIETIC_STEM_CELL_UP   Curated   325                       155                         110                             58.5                                                       **\<2e-4**   **\<2e-4**   **0.001**    0.042        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  KINSEY_TARGETS_OF_EWSR1_FLII\_\       Curated   336                       166                         98                              62.9                                                       **\<2e-4**   **\<2e-4**   **0.001**    0.042        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  FUSION_DN                                                                                                                                                                                                                                                                                   

  BROWNE_HCMV_INFECTION_24HR_DN         Curated   153                       69                          63                              52.3                                                       **\<2e-4**   **\<2e-4**   **0.001**    0.046        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  DELYS_THYROID_CANCER_DN               Curated   214                       109                         86                              55.9                                                       **\<2e-4**   0.013        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  HORIUCHI_WTAP_TARGETS_UP              Curated   323                       147                         119                             55.3                                                       **\<2e-4**   0.013        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  THUM_SYSTOLIC_HEART_FAILURE_DN        Curated   248                       136                         61                              69.0                                                       **0.001**    0.029        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  IWANAGA_CARCINOGENESIS_BY_KRAS\_\     Curated   445                       161                         119                             57.5                                                       **0.001**    0.036        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  PTEN_DN                                                                                                                                                                                                                                                                                     

  SCHUETZ_BREAST_CANCER_DUCTAL\_\       Curated   364                       172                         146                             54.1                                                       **\<2e-4**   **\<2e-4**   **0.001**    0.051        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  INVASIVE_UP                                                                                                                                                                                                                                                                                 

  GRESHOCK_CANCER_COPY_NUMBER_DN        Curated   347                       198                         107                             64.9                                                       **\<2e-4**   **\<2e-4**   **0.002**    0.055        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  CHEBOTAEV_GR_TARGETS_DN               Curated   140                       64                          42                              60.4                                                       **\<2e-4**   **\<2e-4**   **0.003**    0.077        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  GRESHOCK_CANCER_COPY_NUMBER_UP        Curated   322                       195                         107                             64.6                                                       **\<2e-4**   **\<2e-4**   **0.003**    0.084        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  ODONNELL_METASTASIS_UP                Curated   84                        35                          31                              53.0                                                       **\<2e-4**   **\<2e-4**   **0.004**    0.093        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  SENESE_HDAC1_TARGETS_DN               Curated   267                       105                         96                              52.2                                                       **\<2e-4**   **\<2e-4**   **0.004**    0.096        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**

  DAVICIONI_MOLECULAR_ARMS_VS\_\        Curated   339                       179                         113                             61.3                                                       **\<2e-4**   **\<2e-4**   0.015        0.176        **\<2e-4**   **\<2e-4**   **\<2e-4**   **\<2e-4**
  ERMS_UP                                                                                                                                                                                                                                                                                     

  DOANE_RESPONSE_TO_ANDROGEN_DN         Curated   248                       119                         94                              55.9                                                       **0.006**    0.116        **\<2e-4**   **\<2e-4**   **0.001**    0.021        **\<2e-4**   **\<2e-4**

  FOSTER_INFLAMMATORY_RESPONSE\_\       Curated   486                       219                         122                             64.2                                                       0.017        0.205        **\<2e-4**   **\<2e-4**   **\<2e-4**   **0.006**    **\<2e-4**   **\<2e-4**
  LPS_DN                                                                                                                                                                                                                                                                                      

  ACEVEDO_LIVER_CANCER_WITH\_\          Curated   226                       73                          87                              45.6                                                       0.019        0.216        **\<2e-4**   **\<2e-4**   0.210        0.615        **\<2e-4**   **\<2e-4**
  H3K27ME3_DN                                                                                                                                                                                                                                                                                 

  BOYLAN_MULTIPLE_MYELOMA_C\_D_DN       Curated   328                       100                         113                             46.9                                                       0.020        0.224        **\<2e-4**   **\<2e-4**   0.027        0.196        **0.001**    **0.009**

  YAUCH_HEDGEHOG_SIGNALING\_\           Curated   385                       104                         108                             49.1                                                       0.058        0.396        **\<2e-4**   **\<2e-4**   **\<2e-4**   **0.006**    **\<2e-4**   **\<2e-4**
  PARACRINE_DN                                                                                                                                                                                                                                                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*\*Proportion of miRNA target genes was obtained by calculating the number of miRNA target genes divided by the total number of miRNA target genes plus non-miRNA target genes*.

*Empirical *P*-value or FDR~BH~ with values less than 0.01 were shown in bold*.

*GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; GSEA, gene set enrichment analysis; SUM, sum-statistic approach*.

*FDR~BH~, correct for false discovery rates using Benjamini and Hochberg's method*.

*Empirical *P*-value and FDR~BH~ "\<2e−4" meant that no one had greater score than the actual score among the 5,000 permutations for the analysis of each pathway*.
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